OLD National Bancorp IN Cuts Stake in Becton, Dickinson and Company (NYSE:BDX)

OLD National Bancorp IN decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 1.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,963 shares of the medical instruments supplier’s stock after selling 88 shares during the period. OLD National Bancorp IN’s holdings in Becton, Dickinson and Company were worth $1,353,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of BDX. Sound Income Strategies LLC lifted its stake in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares in the last quarter. Central Pacific Bank Trust Division lifted its position in Becton, Dickinson and Company by 22.5% in the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 45 shares in the last quarter. Tompkins Financial Corp boosted its stake in Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the last quarter. Birch Capital Management LLC increased its holdings in shares of Becton, Dickinson and Company by 0.4% in the 3rd quarter. Birch Capital Management LLC now owns 11,773 shares of the medical instruments supplier’s stock worth $2,838,000 after purchasing an additional 48 shares in the last quarter. Finally, Radnor Capital Management LLC raised its stake in shares of Becton, Dickinson and Company by 1.7% in the third quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock worth $708,000 after purchasing an additional 48 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on BDX shares. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Piper Sandler lifted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $283.00.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 4,483 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $221.01, for a total value of $990,787.83. Following the completion of the transaction, the executive vice president now directly owns 24,345 shares in the company, valued at $5,380,488.45. This represents a 15.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Shana Carol Neal sold 788 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the transaction, the executive vice president now directly owns 16,201 shares of the company’s stock, valued at $3,807,235. The trade was a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 9,844 shares of company stock valued at $2,210,716. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.3 %

Becton, Dickinson and Company stock opened at $247.63 on Friday. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $250.91. The company has a market cap of $71.82 billion, a P/E ratio of 41.69, a P/E/G ratio of 1.79 and a beta of 0.39. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The business has a 50-day simple moving average of $230.06 and a two-hundred day simple moving average of $233.66.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The firm’s revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the company earned $3.42 earnings per share. Analysts predict that Becton, Dickinson and Company will post 14.41 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 1.68%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 70.03%.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share repurchase plan on Tuesday, January 28th that authorizes the company to buyback 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.